Daratumumab Combination Therapy for High-Risk Leukemia
Trial Summary
The trial protocol does not specify if you must stop taking your current medications. However, it mentions that you should not have received intensive therapy, chemotherapy, or radiotherapy for 2 weeks before starting the study, except for certain low-dose or maintenance chemotherapies.
Research shows that daratumumab, a key component of the therapy, has been effective in treating various blood cancers, including multiple myeloma and T-cell acute lymphoblastic leukemia (T-ALL), by targeting CD38 on cancer cells. In T-ALL, daratumumab showed significant effectiveness in patient-derived models, suggesting it could be promising for high-risk leukemia.
12345Daratumumab, a monoclonal antibody targeting CD38, has been demonstrated to be safe and effective in patients with refractory multiple myeloma, and it is being explored for other conditions like T-cell acute lymphoblastic leukemia and acute myeloid leukemia. However, it can interfere with blood typing tests, which healthcare professionals are informed about to mitigate risks.
12367The drug 225Ac-DOTA-Anti-CD38 Daratumumab is unique because it combines daratumumab, an antibody targeting CD38, with a radioactive component (225Ac-DOTA), potentially enhancing its ability to target and kill cancer cells in high-risk leukemia. This combination approach is novel compared to standard treatments that typically do not include a radioactive element.
3891011Eligibility Criteria
This trial is for patients with high-risk acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS) who are candidates for donor stem cell transplant. Specific eligibility criteria were not provided, but typically include factors like age, overall health status, and the specifics of their cancer diagnosis.Participant Groups
- Multiple myeloma
- Light chain amyloidosis
- Multiple myeloma
- Light chain amyloidosis